Balloon Retrograde Transvenous Obliteration Versus Endoscopic Cyanoacrylate in Bleeding Gastric Varices: Comparison of Rebleeding and Mortality with Extended Follow-up.
Adult
Aged
Balloon Occlusion
/ adverse effects
Enbucrilate
/ administration & dosage
Esophageal and Gastric Varices
/ diagnosis
Female
Follow-Up Studies
Gastrointestinal Hemorrhage
/ diagnosis
Hemostasis, Endoscopic
/ adverse effects
Humans
Hypertension, Portal
/ complications
Male
Middle Aged
Recurrence
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Journal
Journal of vascular and interventional radiology : JVIR
ISSN: 1535-7732
Titre abrégé: J Vasc Interv Radiol
Pays: United States
ID NLM: 9203369
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
24
07
2018
revised:
05
12
2018
accepted:
06
12
2018
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
7
5
2019
Statut:
ppublish
Résumé
To assess short- and long-term mortality and rebleeding with endoscopic cyanoacrylate (EC) versus balloon-occluded retrograde transvenous obliteration (BRTO). A retrospective cohort comparison was conducted of 90 EC patients and 71 BRTO patients from 1997 through 2015 with portal hypertension who presented due to endoscopically confirmed bleeding cardiofundal gastric varices. Patients underwent either endoscopic intra-varix injection of 4-carbon-n-butyl-2-cyanoacrylate or sclerosis with sodium tetradecyl sulfate with balloon occlusion for primary variceal treatment. Seventy-one BRTO patients and 90 EC patients, of whom 89% had cirrhosis and 35% were women, were included, with a respective average Model for End-Stage Liver Disease (MELD) score of 13.4 and 14.4, respectively. Mortality at 6 weeks was 14.4% for EC patients and 13.1% for BRTO patients (Kaplan-Meier/Wilcoxon, P = .85). No long-term mortality difference was observed (Cox hazard ratio [HR] = 0.89, P = .64). Also, 5.1% of EC patients and 3.5% of BRTO patients (Kaplan-Meier/Wilcoxon, P = .62) rebled at 6 weeks, but at 1 year, 22.0% of EC patients and 3.5% of BRTO patients had rebled (Kaplan-Meier/Wilcoxon, P < .01). Lower rates of long-term rebleeding were found with BRTO (Cox HR = 0.25, P = .03). No difference was seen in the rate of new portal hypertensive complications (Cox HR = 1.21, P = .464). However, 16/71 patients who underwent BRTO had simultaneous transjugular intrahepatic portosystemic shunt. Age, sex, MELD score, and presence of cirrhosis were the primary predictors of mortality. One death in the EC group and 5 deaths in the BRTO group were deemed to be procedurally related (chi-square, P = .088). BRTO is associated with a lower rate of rebleeding but no change in mortality.
Identifiants
pubmed: 30717949
pii: S1051-0443(18)31777-9
doi: 10.1016/j.jvir.2018.12.008
pii:
doi:
Substances chimiques
Enbucrilate
F8CEP82QNP
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-194Informations de copyright
Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved.